Trump’s new FDA head seems to be in Big Pharma’s pocket

From The Fix

According to the Wall Street Journal, Gottlieb made approximately $3 million in speaking, consulting and retainer fees from various medical entities from January 2016 through March 1, 2017. He has stated that he will resign within 90 days from any board, and will divest himself of medical company stocks and recuse himself for a year from making decisions for companies like GlaxoSmithKline.

Ultimately, Gottlieb’s intimate connection with the industry places him in a dangerous position, both for his own agency and for the health care industry. “The worry here is that you’re damned if you do and damned if you don’t,” said Carpenter. “If he’s constantly recusing himself, he can’t function as commissioner, because he’s taking himself out of a wide variety of decisions. But if he doesn’t, then we should worry even more about conflicts of interest.”

Comments are closed.

%d bloggers like this: